Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EQL Pharma AB ( (SE:EQL) ) has provided an announcement.
EQL Pharma AB held its annual general meeting on August 21, 2025, where several key resolutions were adopted. The company decided not to distribute dividends for the financial year 2024/2025, opting instead to carry forward available funds. The meeting also saw the re-election of board members and the introduction of a new long-term incentive program for the CEO, which could result in a slight dilution of shares if all warrants are exercised.
More about EQL Pharma AB
EQL Pharma AB specializes in developing and selling generic drugs that are medically equivalent to original drugs. The company focuses on niche generics with limited competition, primarily in the Nordic and European markets. EQL Pharma AB is based in Lund and is listed on the Nasdaq Stockholm stock market.
Average Trading Volume: 22,360
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK2.48B
For an in-depth examination of EQL stock, go to TipRanks’ Overview page.